1950
DOI: 10.1001/archderm.1950.01530170052006
|View full text |Cite
|
Sign up to set email alerts
|

Podophyllin in the Treatment of Cutaneous Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1953
1953
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 6 publications
0
2
0
Order By: Relevance
“…Podophyllin was first reported in 1946 to demonstrate toxic effects against mitotic cells in similar manner to classical MTAs such as colchicine [113]; this activity was later attributed to the active component podophyllotoxin inhibiting assembly at the mitotic spindle. Despite its original promising ability to inhibit mice tumour growth and potential for translation towards treatment of human malignant tumours [114], unacceptable gastrointestinal toxicity limits its use as a chemotherapeutic agent [115].…”
Section: Podophyllotoxin and Analoguesmentioning
confidence: 99%
“…Podophyllin was first reported in 1946 to demonstrate toxic effects against mitotic cells in similar manner to classical MTAs such as colchicine [113]; this activity was later attributed to the active component podophyllotoxin inhibiting assembly at the mitotic spindle. Despite its original promising ability to inhibit mice tumour growth and potential for translation towards treatment of human malignant tumours [114], unacceptable gastrointestinal toxicity limits its use as a chemotherapeutic agent [115].…”
Section: Podophyllotoxin and Analoguesmentioning
confidence: 99%
“…Podophyllin has also been tried with varying success in the topical treatment of premalignant and malignant skin lesions such as actinic keratoses, keratoacanthoma, basal cell carcinoma, squamous cell carcinoma, and also as a systemic agent in the management of uterine carcinoma. [ 20 21 22 23 24 25 26 27 28 ] However, the mixed response and the high relapse rate forced researchers to abandon its use as an antineoplastic agent.…”
Section: Clinical Usesmentioning
confidence: 99%